In conclusion, rosuvastatin improves glucose intolerance, insulin sensitivity and NAFLD in a dose-dependent manner and changes the fat distribution from visceral to subcutaneous fat depot in a mouse model of diet-induced obesity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.